sudapyridine

Sudapyridine is a small molecule investigational drug developed as a structural analog of bedaquiline. It is designed to treat tuberculosis, particularly rifampicin-resistant (RR), multidrug-resistant (MDR), and extensively drug-resistant (XDR) forms. Sudapyridine acts by inhibiting mycobacterial ATP synthase, thereby disrupting the energy metabolism of Mycobacterium tuberculosis and non-tuberculous mycobacteria. Compared to bedaquiline, sudapyridine retains similar anti-tuberculosis efficacy but was structurally modified to reduce adverse effects such as QT interval prolongation. The compound demonstrates potent in vitro and in vivo activity against both drug-susceptible and drug-resistant strains of M. tuberculosis as well as several non-tuberculous mycobacteria species[3][4][8][9].

Other names

Fudapirine(1R,2S)-1-[5-(4-chlorophenyl)-2-methoxypyridin-3-yl]-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol(αS,βR)-5-(4-Chlorophenyl)-α-[2-(dimethylamino)ethyl]-2-methoxy-α−1-naphthalenyl−β−phenyl−3-pyridineethanol